The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


AstraZeneca ABEU/1/12/795/001-005

Main Information

Trade NameForxiga
Active SubstancesDapagliflozin propanediol monohydrate equivalent to 5mg dapagliflozin
Dosage FormFilm-coated tablet
Licence HolderAstraZeneca AB
Licence NumberEU/1/12/795/001-005

Group Information

ATC CodeA10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10BK01 Dapagliflozin


License statusAuthorised
Licence Issued
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back